Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

UnitedHealth Group logoUnitedHealth Group UNH

The company said consolidated revenues for Q3 2024 grew 9% year over year, UnitedHealthcare revenues grew 7% and Optum revenues grew 13%. Consolidated earnings from operations were $8.7 billion, compared with $8.5 billion a year earlier.

10-QQuarterly reportFiled Period of report Summary published (UTC)

Key points

AI summary
  1. The company said consolidated revenues for Q3 2024 grew 9% year over year, UnitedHealthcare revenues grew 7% and Optum revenues grew 13%. Consolidated earnings from operations were $8.7 billion, compared with $8.5 billion a year earlier.

  2. The company said it had provided interest-free loans of nearly $9 billion to care providers in connection with the Change Healthcare cyberattack through September 30, 2024. It cited direct response costs of $341 million for the 3 months and $1.7 billion for the 9 months.

  3. The company said it completed the sale of its Brazil operations on February 6, 2024 and recorded a loss of $7.1 billion over 9 months, of which $4.1 billion related to the impact of cumulative foreign currency translation losses. The remaining South American operations were classified as held for sale and resulted in a loss of $1.2 billion.

  4. UnitedHealth Group said cash flows from operations for 2024 over the 9 months were $21.8 billion. It said it repurchased approximately 7.7 million shares during the same period at an average price of $521.21, and that as of the balance date it had authorization to repurchase up to 42 million shares.

Key figures

Quarter ended September 30, 2024

Revenue
$100.8B
Operating income
$8.7B
Net income
$6.1B
EPS
$6.51

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

UnitedHealth Group Q3 2024 Revenue and Operating Earnings

The company said consolidated revenues for Q3 2024 grew 9% year over year, UnitedHealthcare revenues grew 7% and Optum revenues grew 13%. Consolidated earnings from operations were $8.7 billion, compared with $8.5 billion a year earlier.

Source · Based on the MD&A text of the filing

Change Healthcare Cyberattack Response Costs

The company said it had provided interest-free loans of nearly $9 billion to care providers in connection with the Change Healthcare cyberattack through September 30, 2024. It cited direct response costs of $341 million for the 3 months and $1.7 billion for the 9 months.

Source · Based on the MD&A text of the filing

Losses on Brazil and South America Divestitures

The company said it completed the sale of its Brazil operations on February 6, 2024 and recorded a loss of $7.1 billion over 9 months, of which $4.1 billion related to the impact of cumulative foreign currency translation losses. The remaining South American operations were classified as held for sale and resulted in a loss of $1.2 billion.

Source · Based on the MD&A text of the filing

Operating Cash Flow and Share Repurchases

UnitedHealth Group said cash flows from operations for 2024 over the 9 months were $21.8 billion. It said it repurchased approximately 7.7 million shares during the same period at an average price of $521.21, and that as of the balance date it had authorization to repurchase up to 42 million shares.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.